Milestone Pharmaceuticals’ CARDAMYST™ Receives Notice of Allowance for Method of Use Patent
On February 19, 2025, Milestone Pharmaceuticals Inc. (MIST), a pioneering biopharmaceutical company specializing in the development and commercialization of innovative cardiovascular medicines, made an exciting announcement. The United States Patent and Trademark Office (USPTO) granted the company a Notice of Allowance for a new Method of Use patent. This patent pertains to etripamil nasal spray, Milestone’s lead investigational product, proposed for the management of paroxysmal supraventricular tachycardia (PSVT).
About Paroxysmal Supraventricular Tachycardia (PSVT)
Paroxysmal Supraventricular Tachycardia is a type of heart rhythm disorder, characterized by rapid, irregular heartbeats that can start and stop suddenly. These episodes can cause symptoms such as palpitations, dizziness, shortness of breath, and fatigue. PSVT can be challenging to manage, as traditional treatments may not be effective for all patients or may cause adverse side effects.
The Role of Etripamil Nasal Spray (CARDAMYST™)
Etripamil nasal spray (CARDAMYST™) is an investigational product that Milestone Pharmaceuticals is developing to address the unmet medical need in the management of PSVT. Etripamil is a selective IK calcium channel blocker that works by slowing the heart rate and reducing the risk of arrhythmias. The nasal spray formulation allows for rapid administration during PSVT episodes, offering a potential advantage over traditional treatments.
Impact on Individuals with PSVT
For individuals with PSVT, the approval of CARDAMYST™ as a treatment option could bring significant relief. The rapid administration of etripamil through a nasal spray may help to terminate PSVT episodes more effectively than current treatments, reducing the frequency and severity of symptoms. This could lead to improved quality of life, reduced healthcare utilization, and decreased anxiety and fear associated with unpredictable PSVT episodes.
Global Implications
The approval of CARDAMYST™ as a treatment for PSVT could have far-reaching implications for the cardiovascular healthcare landscape. The World Health Organization (WHO) estimates that around 2.5 million people worldwide are diagnosed with atrial arrhythmias, including PSVT, each year. With an effective, rapid-acting treatment option like CARDAMYST™, healthcare systems could potentially reduce the burden of PSVT on individuals and healthcare resources.
Conclusion
Milestone Pharmaceuticals’ receipt of a Notice of Allowance for the Method of Use patent on etripamil nasal spray (CARDAMYST™) marks an important step forward in the development of a potential game-changing treatment for paroxysmal supraventricular tachycardia (PSVT). This innovative nasal spray formulation could offer significant benefits for individuals with PSVT, including rapid administration during episodes and improved symptom relief. Furthermore, the global implications of CARDAMYST™’s potential approval could lead to reduced healthcare utilization and improved quality of life for millions of people worldwide living with atrial arrhythmias.
- Milestone Pharmaceuticals receives Notice of Allowance from USPTO for CARDAMYST™’s Method of Use patent
- CARDAMYST™ is an investigational product for the management of paroxysmal supraventricular tachycardia (PSVT)
- Etripamil nasal spray could offer rapid administration and improved symptom relief for individuals with PSVT
- Global implications could lead to reduced healthcare utilization and improved quality of life for millions living with atrial arrhythmias
